RxDoctor Payments Data

Sara Penquite, MD

Endocrinology, Diabetes & Metabolism · Tucson, AZNPI 1528591682

Payments from drug & device makers

$4,088in general payments, 2019–2025

Across 39 payments — averaging $104.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Insulet Corporation$389
  • Dexcom, Inc.$371
  • Corcept Therapeutics$345
  • Chiesi USA, Inc.$325
  • BETA Bionics, Inc.$139
  • plus $421 from 4 others

What the payments were for

  • Speaking & faculty fees$3258%
  • Travel & lodging$1,27131%
  • Food & beverage$2,49161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,088 in reported general payments places this provider in the 55th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona

Medicare billing

Part B allowed, 2024
$42,401
Medicare patients
244
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide77$89,066
MounjaroTirzepatide57$81,659
OzempicSemaglutide48$66,318
JardianceEmpagliflozin25$35,422
Teriparatide12$27,216
FarxigaDapagliflozin Propanediol20$16,962
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$14,441
Tresiba Flextouch U-100Insulin Degludec17$12,949
Humalog Kwikpen U-100Insulin Lispro26$11,726
HumalogInsulin Lispro32$9,510
Gvoke Hypopen 2-PackGlucagon11$6,657
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$6,299
Insulin Lispro Kwikpen U-100Insulin Lispro13$4,455
Hydrocortisone47$2,537
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$2,486

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →